A brief overview of drug-induced liver damage

被引:0
|
作者
Roy, Soumyadip [1 ]
Shah, Zalak [1 ]
Chakraborthy, G. S. [1 ]
机构
[1] Parul Univ, Parul Inst Pharm & Res, Dept Pharmacol, Vadodara, Gujarat, India
关键词
Liver injury; Drug; Hypersensitivity; Toxicity; Serum biomarkers; INDUCED HEPATOTOXICITY; ORAL MEDICATIONS; HEPATITIS-B; CELL-DEATH; INJURY; KERATIN-18; BIOMARKERS; FAILURE; RISK; MECHANISMS;
D O I
10.1186/s43162-024-00315-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drug-induced liver injury (DILI) is a prevalent disorder that can be led on by almost all drug types. The majority of benign DILI cases become better after drug discontinuation. To stop the development of acute or chronic liver failure, it is crucial to identify and get rid of the offending substance as soon as feasible. DILI does not have any identified risk factors, but certain people may be more susceptible due to genetic vulnerability and previous liver disease. Some patients may exhibit indications of systemic hypersensitivity, even though the majority of patients have clinical symptoms that are the same as those of other liver illnesses. Rapid drug withdrawal and supportive care aimed at reducing uncomfortable symptoms comprise the treatment for drug- and herbal-induced liver damage.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Drug-induced Liver Diseases
    Spangenberg, Hans Christian
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (23) : 1688 - U63
  • [2] Drug-Induced Liver Disease
    Davern, Timothy J.
    CLINICS IN LIVER DISEASE, 2012, 16 (02) : 231 - +
  • [3] Drug-Induced Liver Injury
    Leise, Michael D.
    Poterucha, John J.
    Talwalkar, Jayant A.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (01) : 95 - 106
  • [4] Idiosyncratic drug-induced liver injury: an update on the 2007 overview
    Hussaini, S. Hyder
    Farrington, Elizabeth Anne
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (01) : 67 - 81
  • [5] Biomarkers of Drug-Induced Liver Toxicity
    Neuman, Manuela G.
    THERAPEUTIC DRUG MONITORING, 2019, 41 (02) : 227 - 234
  • [6] Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease
    Teschke, Rolf
    Danan, Gaby
    DRUG SAFETY, 2016, 39 (08) : 729 - 744
  • [7] Drug-induced liver injury: an overview over the most critical compounds
    Bjornsson, Einar S.
    ARCHIVES OF TOXICOLOGY, 2015, 89 (03) : 327 - 334
  • [8] Drug Rechallenge Following Drug-Induced Liver Injury
    Hunt, Christine M.
    Papay, Julie I.
    Stanulovic, Vid
    Regev, Arie
    HEPATOLOGY, 2017, 66 (02) : 646 - 654
  • [9] Serum proteomic profiling in patients with drug-induced liver injury
    Bell, L. N.
    Vuppalanchi, R.
    Watkins, P. B.
    Bonkovsky, H. L.
    Serrano, J.
    Fontana, R. J.
    Wang, M.
    Rochon, J.
    Chalasani, N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (05) : 600 - 612
  • [10] Genomic indicators in the blood predict drug-induced liver injury
    Huang, J.
    Shi, W.
    Zhang, J.
    Chou, J. W.
    Paules, R. S.
    Gerrish, K.
    Li, J.
    Luo, J.
    Wolfinger, R. D.
    Bao, W.
    Chu, T-M
    Nikolsky, Y.
    Nikolskaya, T.
    Dosymbekov, D.
    Tsyganova, M. O.
    Shi, L.
    Fan, X.
    Corton, J. C.
    Chen, M.
    Cheng, Y.
    Tong, W.
    Fang, H.
    Bushel, P. R.
    PHARMACOGENOMICS JOURNAL, 2010, 10 (04) : 267 - 277